Item 8.01 Other Events
The information included under Item 7.01 above
is incorporated herein by reference.
Important Information About the Merger and Where to Find
It
A full description of the
terms of the Business Combination will be provided in the registration statement on Form S-4 (the “S-4 Registration Statement”)
to be filed with the SEC by RACA, which will include a prospectus with respect to RACA’s securities to be issued in connection with
the Business Combination and a proxy statement with respect to the stockholder meeting of RACA to vote on the Business Combination. RACA
urges its investors, stockholders and other interested persons to read, when available, the preliminary proxy statement/prospectus as
well as other documents filed with the SEC because these documents will contain important information about RACA, POINT and the Business
Combination. After the S-4 Registration Statement is declared effective, the definitive proxy statement/prospectus to be included in the
registration statement will be mailed to stockholders of RACA as of a record date to be established for voting on the proposed Business
Combination. Once available, stockholders will also be able to obtain a copy of the S-4 Registration Statement, including the proxy statement/prospectus,
and other documents filed with the SEC without charge, by directing a request to: Therapeutics Acquisition Corp., 200 Berkeley Street,
18th Floor, Boston, Massachusetts 02116. The preliminary and definitive proxy statement/prospectus to be included in the S-4
Registration Statement, once available, can also be obtained, without charge, at the SEC’s website (www.sec.gov).
Participants in the Solicitation
RACA and POINT and their
respective directors and executive officers may be considered participants in the solicitation of proxies with respect to the Business
Combination under the rules of the SEC. Information about the directors and executive officers of RACA is set forth in RACA’s
final prospectus filed with the SEC pursuant to Rule 424(b) of the Securities Act on July 9, 2020, and is available free
of charge at the SEC’s website at www.sec.gov or by directing a request to: Therapeutics Acquisition Corp., 200 Berkeley Street,
18th Floor, Boston, Massachusetts 02116. Information regarding the persons who may, under the rules of the SEC, be deemed
participants in the solicitation of RACA’s stockholders in connection with the proposed Business Combination will be set forth in
the registration statement containing the proxy statement/prospectus for the proposed Business Combination when it is filed with the SEC.
These documents can be obtained free of charge from the sources indicated above.
Forward Looking Statements
This Current Report contains forward-looking statements that are based on beliefs and assumptions and on information currently available.
In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,”
“would,” “should,” “expect,” “intend,” “plan,” “anticipate,”
“believe,” “estimate,” “predict,” “project,” “potential,” “continue,”
“ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain
these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance
or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we
believe that we have a reasonable basis for each forward-looking statement contained in this Current Report, we caution you that these
statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot
be certain. Forward-looking statements in this Current Report include, but are not limited to, statements regarding the proposed Business
Combination, including the timing and structure of the Business Combination, the proceeds of the Business Combination, the initial market
capitalization of the combined company following the Closing and the benefits of the Business Combination, as well as statements about
the potential attributes and benefits of POINT’s product candidates and the format and timing of POINT’s product development
activities and clinical trials. We cannot assure you that the forward-looking statements in this Current Report will prove to be accurate.
These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ
materially from expected results, including, among others, the ability to complete the Business Combination due to the failure to obtain
approval from RACA’s stockholders or satisfy other closing conditions in the Business Combination Agreement, the occurrence of
any event that could give rise to the termination of the Business Combination Agreement, the ability to recognize the anticipated benefits
of the Business Combination, the outcome of any legal proceedings that may be instituted against RACA or POINT following announcement
of the proposed Business Combination and related transactions, the impact of COVID-19 on POINT’s business and/or the ability of
the parties to complete the Business Combination, the ability to obtain or maintain the listing of RACA’s common stock
on Nasdaq following the proposed Business Combination, costs related to the proposed Business Combination, changes in applicable laws
or regulations, the possibility that RACA or POINT may be adversely affected by other economic, business, and/or competitive factors.
and other risks and uncertainties, including those to be included under the header “Risk Factors” in the S-4 Registration
Statement to be filed by RACA with the SEC and those included under the header “Risk Factors” in the final prospectus of
RACA related to its initial public offering. Most of these factors are outside RACA’s and POINT’s control and are difficult
to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant
uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any
other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in
this Current Report represent our views as of the date of this Current Report. We anticipate that subsequent events and developments
will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we
have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking
statements as representing our views as of any date subsequent to the date of this Current Report.
No Offer or Solicitation
This Current Report is not
a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed Business
Combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale
of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification
under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting
the requirements of the Securities Act.